



# Advanced Cholangiocarcinoma: A New Era of Mechanisms and Management

## Reference List

- Abou-Alfa G, Macarulla T, Javle MM, et al. Ivosidenib in IDH1- mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomized, double-blind, placebo-controlled, phase 3 study. *Lancet Oncol.* 2020; 21(6):796-807. doi:10.1016/S1470-2045(20)30157-1
- Ahn DH, Bekaii-Saab T. Biliary cancer: intrahepatic cholangiocarcinoma vs. extrahepatic cholangiocarcinoma vs. gallbladder cancers: classification and therapeutic implications. *J Gastrointest Oncol.* (2017) 8(2):293-301. doi:10.21037/jgo.2016.10.01
- Boscoe AN, Rolland C, Kelley RK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. *J Gastrointest Oncol.* 2019;10(4):751-765. doi: 10.21037/jgo.2019.03.10
- Churi CR, Shroff R, Wang Y, et al. Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. *PLoS One.* 2014;9(12):e115383. doi: 10.1371/journal.pone.0115383
- Demols A, Rocq L, Charry M, et al. NTRK gene fusions in biliary tract cancers. *J Clin Oncol.* 2020;38(4 suppl):574.
- Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvisé M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. *Liver Int.* 2019;39(Suppl 1):98-107. doi: 10.1111/liv.14086
- Goeppert B, Frauenschuh L, Renner M, et al. BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma. *Mod Pathol.* 2014;27(7):1028-1034. doi: 10.1038/modpathol.2013.206
- Goyal L, Meric-Bernstam F, Hollebecque A, et al. Updated results of the FOENIX-CCA2 trial: Efficacy and safety of futibatinib in intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements. *J Clin Oncol.* 2022;40(suppl 16):4009. doi:10.1200/JCO.2022.40.16\_suppl.4009.
- Graham RP, Barr Fritcher EG, Pestova E, et al. Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma. *Hum Pathol.* 2014;45(8):1630-1638. doi: 10.1016/j.humpath.2014.03.014
- Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics review, 1975-2014. Bethesda, MD: National Cancer Institute (2017). Available at: [https://seer.cancer.gov/csr/1975\\_2014/](https://seer.cancer.gov/csr/1975_2014/). Based on November 2016 SEER data submission, posted to the SEER web site.
- Kato S, Subbiah V, Marchlik E, et al. *RET* aberrations in diverse cancers: Next-generation sequencing of 4,871 patients. *Clin Cancer Res.* 2017;23(8):1988-1997. doi: 10.1158/1078-0432.CCR-16-1679
- Kelley RK, Ueno M, Yoo C, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2023;401(10391):1853-1865. doi:10.1016/S0140-6736(23)00727-4
- Kommallapti A, Harsha ST, Borad M et al. FGFR inhibitors in oncology: Insight on the management of toxicities in clinical practice. *Cancers.* 2021;13(12):2968. doi: 10.3990/cancers13122968
- Mondesir J, Willekens C, Touat M, de Botton S. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. *J Blood Med.* 2016;7:171-180. doi: 10.2147/JBMS70716



# Advanced Cholangiocarcinoma: A New Era of Mechanisms and Management

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Hepatobiliary Cancers. Version 2.2023. Accessed October 25, 2022.

[https://www.nccn.org/professionals/physician\\_gls/pdf/hepatobiliary.pdf](https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf)

Oh DY, He AR, Qin S, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. *NEJM Evid.* 2022;1(8)1-11. doi:10.1056/EVIDoA2200015

Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. *Oncologist.* 2016;21(5):594-599. doi: 10.1634/theoncologist.2015-0446

TIBSOVO (ivosidenib). Prescribing information. Servier Pharmaceuticals LLC, 2021. Accessed September 15, 2023. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/211192\\_s008lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/211192_s008lbl.pdf)

Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. *Lancet.* 2021;397(10272):428-444. doi:10.1016/s0140-6736(21)00153-7

Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. *N Engl J Med.* 2010;362(14):1273- 1281. doi: 10.1056/NEJMoa0908721

Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with *IDH1* mutation: The phase 3 randomized clinical ClarIDHy trial. *JAMA Oncol.* 2021;7(11):1669-1677. doi: 10.1001/jamaoncol.2021.3836